- call +1-201-465-4211
- email sales@mrinsights.biz
Parkinson's disease (PD) is a long-term degenerative disorder of the central nervous system that mainly affects the motor system.The symptoms generally come on slowly over time.Early in the disease, the most obvious are shaking, rigidity, slowness of movement, and difficulty with walking.Thinking and behavioral problems may also occur.Dementia becomes common in the advanced stages of the disease.Depression and anxiety are also common, occurring in more than a third of people with PD.Other symptoms include sensory, sleep, and emotional problems.The main motor symptoms are collectively called "parkinsonism", or a "parkinsonian syndrome"
Scope of the Report:
This report focuses on the Parkinsons Disease Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for Parkinsons Disease Drugs in US$ by following Product Segments.: Clinical, Experiment
Company profiles are primarily based on public domain information including company
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
The worldwide market for Parkinsons Disease Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Johnson & Johnson
Gilead Sciences
Pacira
Sun Pharmaceutical
Luye Pharma
Sigma-Tau Group
Fudan-Zhangjiang
Teva Pharmaceutical
CSPC
Novartis
Kingond Pharm
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Clinical
Experiment
Market Segment by Applications, can be divided into
Treament
Prevention
There are 15 Chapters to deeply display the global Parkinsons Disease Drugs market.
Chapter 1, to describe Parkinsons Disease Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Parkinsons Disease Drugs, with sales, revenue, and price of Parkinsons Disease Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Parkinsons Disease Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Parkinsons Disease Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Parkinsons Disease Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Parkinsons Disease Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Clinical
1.2.2 Experiment
1.3 Market Analysis by Applications
1.3.1 Treament
1.3.2 Prevention
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Johnson & Johnson
2.1.1 Business Overview
2.1.2 Parkinsons Disease Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Johnson & Johnson Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Gilead Sciences
2.2.1 Business Overview
2.2.2 Parkinsons Disease Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Gilead Sciences Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Pacira
2.3.1 Business Overview
2.3.2 Parkinsons Disease Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Pacira Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Sun Pharmaceutical
2.4.1 Business Overview
2.4.2 Parkinsons Disease Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sun Pharmaceutical Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Luye Pharma
2.5.1 Business Overview
2.5.2 Parkinsons Disease Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Luye Pharma Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Sigma-Tau Group
2.6.1 Business Overview
2.6.2 Parkinsons Disease Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Sigma-Tau Group Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Fudan-Zhangjiang
2.7.1 Business Overview
2.7.2 Parkinsons Disease Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Fudan-Zhangjiang Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Teva Pharmaceutical
2.8.1 Business Overview
2.8.2 Parkinsons Disease Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Teva Pharmaceutical Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 CSPC
2.9.1 Business Overview
2.9.2 Parkinsons Disease Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 CSPC Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Novartis
2.10.1 Business Overview
2.10.2 Parkinsons Disease Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Novartis Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Kingond Pharm
2.11.1 Business Overview
2.11.2 Parkinsons Disease Drugs Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Kingond Pharm Parkinsons Disease Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Parkinsons Disease Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Parkinsons Disease Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Parkinsons Disease Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Parkinsons Disease Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Parkinsons Disease Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Parkinsons Disease Drugs Market Analysis by Regions
4.1 Global Parkinsons Disease Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Parkinsons Disease Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Parkinsons Disease Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
4.5 South America Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
5 North America Parkinsons Disease Drugs by Countries
5.1 North America Parkinsons Disease Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Parkinsons Disease Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Parkinsons Disease Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
6 Europe Parkinsons Disease Drugs by Countries
6.1 Europe Parkinsons Disease Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Parkinsons Disease Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Parkinsons Disease Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
6.3 UK Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
6.4 France Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Parkinsons Disease Drugs by Countries
7.1 Asia-Pacific Parkinsons Disease Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Parkinsons Disease Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Parkinsons Disease Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
7.5 India Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
8 South America Parkinsons Disease Drugs by Countries
8.1 South America Parkinsons Disease Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Parkinsons Disease Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Parkinsons Disease Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Parkinsons Disease Drugs by Countries
9.1 Middle East and Africa Parkinsons Disease Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Parkinsons Disease Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Parkinsons Disease Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Parkinsons Disease Drugs Sales and Growth Rate (2013-2018)
10 Global Parkinsons Disease Drugs Market Segment by Type
10.1 Global Parkinsons Disease Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Parkinsons Disease Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Parkinsons Disease Drugs Revenue and Market Share by Type (2013-2018)
10.2 Clinical Sales Growth and Price
10.2.1 Global Clinical Sales Growth (2013-2018)
10.2.2 Global Clinical Price (2013-2018)
10.3 Experiment Sales Growth and Price
10.3.1 Global Experiment Sales Growth (2013-2018)
10.3.2 Global Experiment Price (2013-2018)
11 Global Parkinsons Disease Drugs Market Segment by Application
11.1 Global Parkinsons Disease Drugs Sales Market Share by Application (2013-2018)
11.2 Treament Sales Growth (2013-2018)
11.3 Prevention Sales Growth (2013-2018)
12 Parkinsons Disease Drugs Market Forecast (2018-2023)
12.1 Global Parkinsons Disease Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Parkinsons Disease Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Parkinsons Disease Drugs Market Forecast (2018-2023)
12.2.2 Europe Parkinsons Disease Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Parkinsons Disease Drugs Market Forecast (2018-2023)
12.2.4 South America Parkinsons Disease Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Parkinsons Disease Drugs Market Forecast (2018-2023)
12.3 Parkinsons Disease Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Parkinsons Disease Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Parkinsons Disease Drugs Market Share Forecast by Type (2018-2023)
12.4 Parkinsons Disease Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Parkinsons Disease Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Parkinsons Disease Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Parkinsons Disease Drugs Picture
Table Product Specifications of Parkinsons Disease Drugs
Figure Global Sales Market Share of Parkinsons Disease Drugs by Types in 20
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
